Valneva SE

Campus Bio-Ouest
44800 Saint-Herblain
France

Contact WebSite

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.

Article

Pfizer Invests in Valneva, Updates Lyme Vaccine Venture
21.06.2022 • News

Pfizer Invests in Valneva, Updates Lyme Vaccine Venture

Pfizer is to invest $95 million and take an equity share of 8.1% in in Valneva in order to further support development of a vaccine for Lyme disease.